Page 4 - Tim Lu News Today

/PRNewswire/ -- Lunit, a leading medical AI provider, today announced it has raised $61 million in its Pre-IPO fundraising round ahead of the companys planned...

- New investors include US life science investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, and Asia-based global healthcare investors Tybourne Capital Management

Senti Bio Adds Prominent Scientific and Industry Leaders to its Scientific Advisory Board - read this article along with other careers information, tips and advice on BioSpace

The Microbiome Gains Momentum in Cancer Immunotherapy The Microbiome Gains Momentum in Cancer Immunotherapy Vedanta Biosciences develops drugs made from defined bacterial consortia. One of these drugs, a cancer drug called VE800, addresses a challenge that may commonly occur with microbiome-engaging cancer immunotherapeutics. The problem is variability in microbiome signatures. Vedanta’s CEO, Bernat Olle, PhD, says that with cancer, there is no “night and day type of signature” like that...

Meet Nargiz Ali Zada, an international student earning her MaineMBA. Find out what drew Nargiz to UMaine from Azerbaijan and why earning an MBA is important to her. Tell us a little bit about where you are from… I am from Baku, the capital city of Azerbaijan. Baku is an ancient, beautiful city on the coast of the Caspian Sea. It’s an important center for oil production. There are many historical monuments such as Gobustan, one of the oldest human settlements with more than 6,000 ancient ro...

Icepack | Jan. 28-Feb. 4 Let’s start with something frivolous for once: Philly football (because how serious can anybody on that team – front office or backfield be – what with the stupid decisions they’ve all made since their last Super Bowl win) and the hiring of young Nick Sirianni as the Philadelphia Eagles new head coach.  One, is there really a whiff of racism to be smelt and dealt among the Eagles executive branch, as is rumored, considering how longtime Eagles assistant head co...

Senti Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) — Senti Bio, a leading gene circuit company, today announced that Dr. Tim Lu, the CEO of Senti Bio, will present a corporate overview at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 th at 2:35 p.m. ET. After Dr. Lu’s prepared remarks, Senti Bio will make the presentation available on its website. About Senti Bio Sent...

(2) Senti Bios gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round. The fin...

(Getty Images) Leaps by Bayer has led a chunky $105 million series B round for next-gen gene therapy player Senti Biosciences. Nearly three years after its initial $53 million series A, Senti Bio now has now doubled its funding, adding Bayer’s VC arm into the mix and continuing in 2021 its ongoing mission to become a broad gene therapy player. Fierce 15 winner Senti Bio’s approach involves what it calls “gene circuits,” essentially tweaking a cell’s genetic code which can mor...